Vaxcyte Inc. (NASDAQ:PCVX) is one of the most promising mid-cap healthcare stocks under $50. On December 9, BTIG analyst Thomas Shrader reiterated his bullish view of Vaxcyte Inc. (NASDAQ:PCVX). He assigned a Buy rating to the stock with a target price of $85. This results in an upside of over 83% from the current level. Sharder mentioned the positive results from Phase 2 trials for the VAX-31 vaccine, which will prove to be a building block for the critical Phase 3 trials. The upcoming trial’s robust d ...